The Risk of Overall Mortality in Patients with Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy: a Retrospective Analysis

Overview

Journal Diabetes Care

Specialty Endocrinology

Date 2010 Mar 11

PMID 20215447

Citations 26

Authors

Kevin M Pantalone

Michael W Kattan

Changhong Yu

Brian J Wells

Susana Arrigain

Anil Jain

Ashish Atreja

Robert S Zimmerman

Affiliations

Soon will be listed here.

Abstract

Objective: Sulfonylureas have historically been analyzed as a medication class, which may be inappropriate given the differences in properties inherent to the individual sulfonylureas (hypoglycemic risk, sulfonylurea receptor selectivity, and effects on myocardial ischemic preconditioning). The purpose of this study was to assess the relationship of individual sulfonylureas and the risk of overall mortality in a large cohort of patients with type 2 diabetes.

Research Design And Methods: A retrospective cohort study was conducted using an academic health center enterprise-wide electronic health record (EHR) system to identify 11,141 patients with type 2 diabetes (4,279 initiators of monotherapy with glyburide, 4,325 initiators of monotherapy with glipizide, and 2,537 initiators of monotherapy with glimepiride), >or=18 years of age with and without a history of coronary artery disease (CAD) and not on insulin or a noninsulin injectable at baseline. The patients were followed for mortality by documentation in the EHR and Social Security Death Index. Multivariable Cox models were used to compare cohorts.

Results: No statistically significant difference in the risk of overall mortality was observed among these agents in the entire cohort, but we did find evidence of a trend toward an increased overall mortality risk with glyburide versus glimepiride (hazard ratio 1.36 [95% CI 0.96-1.91]) and glipizide versus glimepiride (1.39 [0.99-1.96]) in those with documented CAD.

Conclusions: Our results did not identify an increased mortality risk among the individual sulfonylureas but did suggest that glimepiride may be the preferred sulfonylurea in those with underlying CAD.

Citing Articles

Clinical Evidence and Practice-Based Guidelines on the Utility of Basal Insulin Combined Oral Therapy (Metformin and Glimepiride) in the Current Era.

Shrivastava A, Kesavadev J, Mohan V, Saboo B, Shrestha D, Maheshwari A Curr Diabetes Rev. 2023; 19(8):e090123212444.

PMID: 36624650 PMC: 10617787. DOI: 10.2174/1573399819666230109104300.

Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease.

Yagyu H, Shimano H J Diabetes Investig. 2022; 13(9):1472-1488.

PMID: 35638331 PMC: 9434581. DOI: 10.1111/jdi.13859.

Unravelling the utility of modern sulfonylureas from cardiovascular outcome trials and landmark trials: expert opinion from an international panel.

Kalra S, Ghosh S, Das A, Nair T, Bajaj S, Priya G Indian Heart J. 2020; 72(1):7-13.

PMID: 32423565 PMC: 7231843. DOI: 10.1016/j.ihj.2020.01.001.

Linking glycemic dysregulation in diabetes to symptoms, comorbidities, and genetics through EHR data mining.

Kirk I, Simon C, Banasik K, Holm P, Haue A, Jensen P Elife. 2019; 8.

PMID: 31818369 PMC: 6904221. DOI: 10.7554/eLife.44941.

Glucocrinology of Modern Sulfonylureas: Clinical Evidence and Practice-Based Opinion from an International Expert Group.

Kalra S, Das A, Baruah M, Unnikrishnan A, Dasgupta A, Shah P Diabetes Ther. 2019; 10(5):1577-1593.

PMID: 31267358 PMC: 6778594. DOI: 10.1007/s13300-019-0651-1.

References

Song D, Ashcroft F . Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels. Br J Pharmacol. 2001; 133(1):193-9. PMC: 1572773. DOI: 10.1038/sj.bjp.0704062. View

Khalangot M, Tronko M, Kravchenko V, Kovtun V . Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract. 2009; 86(3):247-53. DOI: 10.1016/j.diabres.2009.09.008. View

Mocanu M, Maddock H, Baxter G, Lawrence C, Standen N, Yellon D . Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation. 2001; 103(25):3111-6. DOI: 10.1161/01.cir.103.25.3111. View

Johnson J, Majumdar S, Simpson S, Toth E . Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002; 25(12):2244-8. DOI: 10.2337/diacare.25.12.2244. View

Gribble F, Reimann F . Sulphonylurea action revisited: the post-cloning era. Diabetologia. 2003; 46(7):875-91. DOI: 10.1007/s00125-003-1143-3. View

. The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of pheniformin therapy. Diabetes. 1975; 24 Suppl 1:65-184. View

Hellman B, Sehlin J, Taljedal I . Glibenclamide is exceptional among hypoglycaemic sulphonylureas in accumulating progressively in beta-cell-rich pancreatic islets. Acta Endocrinol (Copenh). 1984; 105(3):385-90. DOI: 10.1530/acta.0.1050385. View

Gross G, Auchampach J . Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res. 1992; 70(2):223-33. DOI: 10.1161/01.res.70.2.223. View

Grover G, Sleph P, Dzwonczyk S . Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interaction with adenosine A1-receptors. Circulation. 1992; 86(4):1310-6. DOI: 10.1161/01.cir.86.4.1310. View

10.

Tomai F, Crea F, Gaspardone A, Versaci F, De Paulis R, Penta de Peppo A . Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation. 1994; 90(2):700-5. DOI: 10.1161/01.cir.90.2.700. View

11.

Gribble F, Tucker S, Seino S, Ashcroft F . Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels. Diabetes. 1998; 47(9):1412-8. DOI: 10.2337/diabetes.47.9.1412. View

12.

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

13.

Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker K . Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J. 1999; 20(6):439-46. DOI: 10.1053/euhj.1998.1242. View

14.

Ashcroft F, Gribble F . ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia. 1999; 42(8):903-19. DOI: 10.1007/s001250051247. View

15.

Johnson J, Simpson S, Toth E, Majumdar S . Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. Diabet Med. 2005; 22(4):497-502. DOI: 10.1111/j.1464-5491.2005.01448.x. View

16.

Szoke E, Gosmanov N, Sinkin J, Nihalani A, Fender A, Cryer P . Effects of glimepiride and glyburide on glucose counterregulation and recovery from hypoglycemia. Metabolism. 2005; 55(1):78-83. DOI: 10.1016/j.metabol.2005.07.009. View

17.

Evans J, Ogston S, Emslie-Smith A, Morris A . Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006; 49(5):930-6. DOI: 10.1007/s00125-006-0176-9. View

18.

Gangji A, Cukierman T, Gerstein H, Goldsmith C, Clase C . A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007; 30(2):389-94. DOI: 10.2337/dc06-1789. View

19.

Evans J, Ogston S, Reimann F, Gribble F, Morris A, Pearson E . No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: a cohort analysis. Diabetes Obes Metab. 2007; 10(4):350-2. PMC: 7237236. DOI: 10.1111/j.1463-1326.2007.00833.x. View

20.

Tayek J . SUR receptor activity vs. incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics. Diabetes Obes Metab. 2008; 10(11):1128-9. DOI: 10.1111/j.1463-1326.2008.00928.x. View